Meeting
2015 ASCO Annual Meeting
Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.
Authors
Ignace Vergote
University Hospital Leuven, Leuven, Belgium
Ignace Vergote , Bente Lund , Hanne Havsteen , Zaza Ujmajuridze , Karin Leunen , Charlotte Aaquist Haslund , Trine Juhler-Noettrup , Henrik Roed , Tami Rashal , Anne L. Kranich , Yosef Landesman , Jean-Richard Saint-Martin , Robert Carlson , Sharon Shacham , Michael Kauffman , Mansoor Raza Mirza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02025985
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5565)
DOI
10.1200/jco.2015.33.15_suppl.5565
Abstract #
5565
Poster Bd #
123
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen
Poster
2020 ASCO Virtual Scientific Program
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2023 ASCO Annual Meeting
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.
First Author: Ignace Vergote